Matrix Partners China and Citic Private Equity Funds Management co-led the series B round, which will fund development of treatments for rare medical conditions.

Triastek, a China-based 3D printed drug developer backed by pharmaceutical company Tasly Holding Group, has secured RMB330m ($51m) in series B funding, DealStreetAsia reported yesterday.

The round was co-led by venture capital firm Matrix Partners China and alternative asset manager Citic Private Equity Funds Management, which invested alongside Shanghai Technology Innovation Fund and venture capital firm Yunqi Partners.

Founded in 2015, Triastek is developing 3D printed drugs using melt extrusion deposition (MED) technology, which allows active pharmaceutical ingredients to be…